Literature DB >> 33416012

Access to and interest in assistive technology for home-dwelling people with dementia during the COVID-19 pandemic (PAN.DEM).

Marie H Gedde1,2, Bettina S Husebo1,3, Ane Erdal1, Nathalie G Puaschitz4, Maarja Vislapuu1, Renira C Angeles5, Line I Berge1,6.   

Abstract

The COVID-19 restrictions affect daily living in Norway, including home-dwelling people with dementia, and researchers conducting clinical trials in dementia care. In this paper, we 1) describe the development of a pandemic cohort (PAN.DEM) incorporated in the LIVE@Home.Path, an ongoing clinical intervention trial on resource utilisation including home-dwelling people with dementia and their caregivers (N = 438 dyads), 2) describe pre-pandemic use of assistive technology and 3) explore the extent to which COVID-19 restrictions increase caregivers interest in innovation in the PAN.DEM cohort (N = 126). Our main finding is that assistive technology is available to 71% pre-pandemic; the vast majority utilise traditional stove guards and safety alarms, only a few operate sensor technology, including GPS, fall detectors or communication aids. In response to COVID-19, 17% show increased interest in technology; being less familiar with operating a telephone and having higher cognitive functioning are both associated with increased interest. We conclude that wearable and sensor technology has not yet been fully implemented among people with dementia in Norway, and few caregivers show increased interest under the restrictions. Clinicaltrials.gov (NCT0404336).

Entities:  

Keywords:  COVID-19; assistive technology; caregivers; dementia; home

Mesh:

Year:  2021        PMID: 33416012     DOI: 10.1080/09540261.2020.1845620

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN: 0954-0261


  6 in total

1.  The impact of medication reviews by general practitioners on psychotropic drug use and behavioral and psychological symptoms in home-dwelling people with dementia: results from the multicomponent cluster randomized controlled LIVE@Home.Path trial.

Authors:  Marie H Gedde; Bettina S Husebo; Janne Mannseth; Mala Naik; Geir Selbaek; Maarja Vislapuu; Line Iden Berge
Journal:  BMC Med       Date:  2022-05-26       Impact factor: 11.150

2.  Cognitive Outcomes During COVID-19 Confinement Among Older People and Their Caregivers Using Technologies for Dementia: Protocol for an Observational Cohort Study.

Authors:  Jessica Marian Goodman-Casanova; Elena Dura-Perez; Gloria Guerrero-Pertiñez; Pilar Barnestein-Fonseca; Jose Guzman-Parra; Amanda Vega-Nuñez; Esperanza Varela-Moreno; Antonio Cuesta-Vargas; Fermin Mayoral-Cleries
Journal:  JMIR Res Protoc       Date:  2021-05-18

3.  Impact of COVID-19 restrictions on behavioural and psychological symptoms in home-dwelling people with dementia: a prospective cohort study (PAN.DEM).

Authors:  Marie H Gedde; Bettina S Husebo; Ipsit V Vahia; Janne Mannseth; Maarja Vislapuu; Mala Naik; Line I Berge
Journal:  BMJ Open       Date:  2022-01-24       Impact factor: 2.692

4.  Two Years of COVID-19: Understanding Impact and Implications for the Mental Health of Older Adults.

Authors:  Hailey V Cray; Ipsit V Vahia
Journal:  Am J Geriatr Psychiatry       Date:  2022-02-14       Impact factor: 4.105

5.  On the Use of Assistive Technology during the COVID-19 Outbreak: Results and Lessons Learned from Pilot Studies.

Authors:  Laura Fiorini; Erika Rovini; Sergio Russo; Lara Toccafondi; Grazia D'Onofrio; Federica Gabriella Cornacchia Loizzo; Manuele Bonaccorsi; Francesco Giuliani; Gianna Vignani; Daniele Sancarlo; Antonio Greco; Filippo Cavallo
Journal:  Sensors (Basel)       Date:  2022-09-02       Impact factor: 3.847

6.  The acceptability, adoption, and feasibility of a music application developed using participatory design for home-dwelling persons with dementia and their caregivers. The "Alight" app in the LIVE@Home.Path trial.

Authors:  Line Iden Berge; Marie Hidle Gedde; Juan Carlos Torrado Vidal; Bettina Husebo; Kia Minna Hynninen; Solgunn Elisabeth Knardal; Kristine Gustavsen Madsø
Journal:  Front Psychiatry       Date:  2022-08-18       Impact factor: 5.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.